This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Obesity-focused Orexigen Therapeutics netted $81.6mm through a follow-on public offering of 10mm common shares (including the overallotment) at $7.50. The company plans to use part of the proceeds to prepare the NDA for its lead Contrave, and for ongoing Phase II trials of Empatic. Both candidates are under development for weight loss.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?